Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine

Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2011, Pages 389-396

  Stout, Stephen M ^a,d   Nielsen, Jace ^a,e   Welage, Lynda S ^a,b   Shea, Michael ^c   Brook, Robert ^c   Kerber, Kevin ^c   Bleske, Barry E ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Lexi Comp Inc   (United States)

^e ANN ARBOR PHARMACOMETRICS GROUP   (United States)

Author keywords

CYP2D6; cytochrome P 450; drug interactions; Metoprolol; paroxetine; pharmacokinetics

Indexed keywords

METOPROLOL; METOPROLOL SUCCINATE; PAROXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PANIC; RANDOMIZED CONTROLLED TRIAL; STEREOCHEMISTRY;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; YOUNG ADULT;

EID: 79953827842     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010365559     Document Type: Article

References (13)

1. Boucher M, Duchêne-Marullaz P, Moundanga JL. Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs. Br J Pharmacol. 1986;89:119-127. (Pubitemid 16031211)
2. Wahlund G, Nerme V, Abramsson T, Sjöquist PO. The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol. Br J Pharmacol. 1990;99:592-596. (Pubitemid 20069169)
3. Borg KO, Carlsson E, Hoffmann KJ, Jönsson TE, Thorin H, Wallin B. Metabolism of metoprolol-(3-h) in man, the dog, and the rat. Acta Pharmacol Toxicol (Copenh). 1975;35(suppl 5):125-135.
4. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988;247:242-247.
5. Dayer P, Leemann T, Marmy A, Rosenthaler J. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol. 1985;28:149-153. (Pubitemid 15143775)
6. Jonkers RE, Koopmans RP, Portier EJ, van Boxtel CJ. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther. 1991;256:959-966.
7. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther. 1983;34:732-737. (Pubitemid 14219918)
8. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 2000;67:283-291. (Pubitemid 30176387)
9. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol. 2008;64:275-282.
10. Bleske BE, Welage LS, Rose S, Amidon GL, Shea MJ. The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. J Clin Pharmacol. 1995;35:374-378.
11. Bleske BE, Welage LS, Touchette MA, Edwards DJ, Rodman DP, Shea MJ. Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmaocokinetic parameters. Ther Drug Monit. 1994;16:216-220. (Pubitemid 24096632)
12. Karim A, Piergies A. Verapimil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Clin Pharmacol Ther. 1995;58:174-184.
13. Onalan O, Cumurcu B, Bekar L. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc. 2008;83:595-599.